131 related articles for article (PubMed ID: 35119175)
21. Transplantation for MDS in the elderly: more evidence, or more bias?
Cutler C
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1320-1. PubMed ID: 22750646
[No Abstract] [Full Text] [Related]
22. Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization.
Serrao A; Loglisci G; Salaroli A; Zacheo I; Alimena G; Breccia M
Leuk Lymphoma; 2013 Feb; 54(2):411-2. PubMed ID: 22694794
[No Abstract] [Full Text] [Related]
23. Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay.
Stieglitz E; Gu CJ; Richardson M; Kita R; Santaguida MT; Ali KA; Strachan DC; Dhar A; Yam G; Anderson W; Anderson E; Hübner J; Tasian SK; Loh ML; Lacher MD
JCO Precis Oncol; 2023 Sep; 7():e2300302. PubMed ID: 37944074
[TBL] [Abstract][Full Text] [Related]
24. Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders.
Niscola P; Siniscalchi A; Tendas A; Scaramucci L; Fratoni S; de Fabritiis P; Caravita T
Ann Hematol; 2015 Oct; 94(10):1753-4. PubMed ID: 26088814
[No Abstract] [Full Text] [Related]
25. First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.
Schroeder T; Kobbe G
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1703-4. PubMed ID: 26277403
[No Abstract] [Full Text] [Related]
26. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia.
Drummond MW; Pocock C; Boissinot M; Mills J; Brown J; Cauchy P; Cross NC; Hartley S; Kell J; Szubert A; Cockerill PN; Bowen DT
Leukemia; 2014 Jul; 28(7):1570-2. PubMed ID: 24569776
[No Abstract] [Full Text] [Related]
27. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
28. Central nervous system lesions due to juvenile myelomonocytic leukemia progressed in a boy undergoing first line chemotherapy.
Fukushima H; Fukushima T; Hiraki A; Suzuki R; Mahmoud SS; Yoshimi A; Nakao T; Kato K; Kobayashi C; Koike K; Fukasawa M; Morishita Y; Doisaki S; Muramatsu H; Sumazaki R
Int J Hematol; 2012 May; 95(5):581-4. PubMed ID: 22461033
[TBL] [Abstract][Full Text] [Related]
29. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
[TBL] [Abstract][Full Text] [Related]
30. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
[TBL] [Abstract][Full Text] [Related]
31. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
[TBL] [Abstract][Full Text] [Related]
32. Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
Niscola P; Tendas A; Abruzzese E; Caravita T; Cupelli L; Giovannini M; Scaramucci L; Siniscalchi A; Trawinska MM; de Fabritiis P
Ann Hematol; 2017 Sep; 96(9):1591-1593. PubMed ID: 28702776
[No Abstract] [Full Text] [Related]
33. Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation.
Sumi M; Kitahara M; Shishido T; Kazumoto H; Uematsu N; Kirihara T; Sato K; Ueki T; Hiroshima Y; Kobayashi H
Intern Med; 2020 Nov; 59(21):2763-2767. PubMed ID: 32641650
[TBL] [Abstract][Full Text] [Related]
34. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Locatelli F; Algeri M; Merli P; Strocchio L
Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
[TBL] [Abstract][Full Text] [Related]
35. Azacitidine Use After Allogeneic Stem Cell Transplantation-Results From the Polish Adult Leukemia Group.
Drozd-Sokołowska J; Gil L; Waszczuk-Gajda A; Mądry K; Piekarska A; Dutka M; Basak GW; Karakulska-Prystupiuk E; Dwilewicz-Trojaczek J
Transplant Proc; 2016 Jun; 48(5):1802-5. PubMed ID: 27496495
[TBL] [Abstract][Full Text] [Related]
36. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
[No Abstract] [Full Text] [Related]
37. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
Keating GM
Drugs; 2009; 69(17):2501-18. PubMed ID: 19911860
[TBL] [Abstract][Full Text] [Related]
38. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Maples KT; Sabo RT; McCarty JM; Toor AA; Hawks KG
Leuk Lymphoma; 2018 Dec; 59(12):2836-2841. PubMed ID: 29616863
[TBL] [Abstract][Full Text] [Related]
39. Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.
Patel SA; Coulter DW; Grovas AC; Gordon BG; Harper JL; Warkentin PI; Wisecarver JL; Sanger WG; Coccia PF
J Pediatr Hematol Oncol; 2014 Aug; 36(6):491-4. PubMed ID: 24322499
[TBL] [Abstract][Full Text] [Related]
40. Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.
Hilmi M; Bally C; Burns R; Lorillon G; Bergeron A; Fenaux P; Ades L
Ann Hematol; 2018 Mar; 97(3):541-542. PubMed ID: 29170809
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
